Boundless Bio, Inc. (BOLD) - Form 8-K Summary
Business Context and Reporting Period
Boundless Bio, Inc., a Delaware corporation, filed this Current Report on Form 8-K on November 5, 2025. The filing serves to announce the Company's financial results for the quarter ended September 30, 2025. The Company is an emerging growth company and its common stock trades on the Nasdaq Global Select Market under the symbol "BOLD."
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report references a press release (Exhibit 99.1) containing the detailed financial results for the quarter ended September 30, 2025, but the figures themselves are not embedded in the provided 8-K text.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text. The document acts as a notification of the results announcement rather than a detailed comparative analysis.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors within the main body text. It explicitly states that the information in the report and the attached press release is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, limiting its incorporation by reference unless specifically stated otherwise in future filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2025 revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the attached exhibit.
- Confirm the status of the Company's emerging growth company election and any related accounting standard transitions.